skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Discovery of a Highly Selective Tankyrase Inhibitor Displaying Growth Inhibition Effects against a Diverse Range of Tumor Derived Cell Lines

Authors:
 [1];  [1];  [1];  [2];  [1];  [1];  [1];  [1];  [2];  [1];  [1];  [1];  [1];  [3];  [1];  [4]; ORCiD logo [1]
  1. Cellzome GmbH, A GlaxoSmithKline Company, Meyerhofstraße 1, 69117 Heidelberg, Germany
  2. GlaxoSmithKline, Research Triangle Park, 5 Moore Drive, North Carolina 27709, United States
  3. Protein, Cellular &, Structural Sciences, GlaxoSmithKline, 1250 South Collegeville Road, Upper Providence, Pennsylvania 19426, United States
  4. Virtual Proof of Concept DPU, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
Publication Date:
Research Org.:
Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Org.:
INDUSTRY
OSTI Identifier:
1374630
Resource Type:
Journal Article
Resource Relation:
Journal Name: Journal of Medicinal Chemistry; Journal Volume: 60; Journal Issue: 13
Country of Publication:
United States
Language:
ENGLISH

Citation Formats

Thomson, Douglas W., Wagner, Anne J., Bantscheff, Marcus, Benson, R. Edward, Dittus, Lars, Duempelfeld, Birgit, Drewes, Gerard, Krause, Jana, Moore, John T., Mueller, Katrin, Poeckel, Daniel, Rau, Christina, Salzer, Elsa, Shewchuk, Lisa, Hopf, Carsten, Emery, John G., and Muelbaier, Marcel. Discovery of a Highly Selective Tankyrase Inhibitor Displaying Growth Inhibition Effects against a Diverse Range of Tumor Derived Cell Lines. United States: N. p., 2017. Web. doi:10.1021/acs.jmedchem.7b00137.
Thomson, Douglas W., Wagner, Anne J., Bantscheff, Marcus, Benson, R. Edward, Dittus, Lars, Duempelfeld, Birgit, Drewes, Gerard, Krause, Jana, Moore, John T., Mueller, Katrin, Poeckel, Daniel, Rau, Christina, Salzer, Elsa, Shewchuk, Lisa, Hopf, Carsten, Emery, John G., & Muelbaier, Marcel. Discovery of a Highly Selective Tankyrase Inhibitor Displaying Growth Inhibition Effects against a Diverse Range of Tumor Derived Cell Lines. United States. doi:10.1021/acs.jmedchem.7b00137.
Thomson, Douglas W., Wagner, Anne J., Bantscheff, Marcus, Benson, R. Edward, Dittus, Lars, Duempelfeld, Birgit, Drewes, Gerard, Krause, Jana, Moore, John T., Mueller, Katrin, Poeckel, Daniel, Rau, Christina, Salzer, Elsa, Shewchuk, Lisa, Hopf, Carsten, Emery, John G., and Muelbaier, Marcel. Mon . "Discovery of a Highly Selective Tankyrase Inhibitor Displaying Growth Inhibition Effects against a Diverse Range of Tumor Derived Cell Lines". United States. doi:10.1021/acs.jmedchem.7b00137.
@article{osti_1374630,
title = {Discovery of a Highly Selective Tankyrase Inhibitor Displaying Growth Inhibition Effects against a Diverse Range of Tumor Derived Cell Lines},
author = {Thomson, Douglas W. and Wagner, Anne J. and Bantscheff, Marcus and Benson, R. Edward and Dittus, Lars and Duempelfeld, Birgit and Drewes, Gerard and Krause, Jana and Moore, John T. and Mueller, Katrin and Poeckel, Daniel and Rau, Christina and Salzer, Elsa and Shewchuk, Lisa and Hopf, Carsten and Emery, John G. and Muelbaier, Marcel},
abstractNote = {},
doi = {10.1021/acs.jmedchem.7b00137},
journal = {Journal of Medicinal Chemistry},
number = 13,
volume = 60,
place = {United States},
year = {Mon Mar 27 00:00:00 EDT 2017},
month = {Mon Mar 27 00:00:00 EDT 2017}
}
  • Purpose: c-Met is overexpressed in some non-small cell lung cancer (NSCLC) cell lines and tissues. Cell lines with higher levels of c-Met expression and phosphorylation depend on this receptor for survival. We studied the effects of AMG-458 on 2 NSCLC cell lines. Methods and Materials: 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl) -2H-tetrazolium assays assessed the sensitivities of the cells to AMG-458. Clonogenic survival assays illustrated the radiosensitizing effects of AMG-458. Western blot for cleaved caspase 3 measured apoptosis. Immunoblotting for c-Met, phospho-Met (p-Met), Akt/p-Akt, and Erk/p-Erk was performed to observe downstream signaling. Results: AMG-458 enhanced radiosensitivity in H441 but not in A549. H441 showed constitutivemore » phosphorylation of c-Met. A549 expressed low levels of c-Met, which were phosphorylated only in the presence of exogenous hepatocyte growth factor. The combination of radiation therapy and AMG-458 treatment was found to synergistically increase apoptosis in the H441 cell line but not in A549. Radiation therapy, AMG-458, and combination treatment were found to reduce p-Akt and p-Erk levels in H441 but not in A549. H441 became less sensitive to AMG-458 after small interfering RNA knockdown of c-Met; there was no change in A549. After overexpression of c-Met, A549 became more sensitive, while H441 became less sensitive to AMG-458. Conclusions: AMG-458 was more effective in cells that expressed higher levels of c-Met/p-Met, suggesting that higher levels of c-Met and p-Met in NSCLC tissue may classify a subset of tumors that are more sensitive to molecular therapies against this receptor.« less
  • Purpose: Toward improved glioblastoma multiforme treatment, we determined whether celecoxib, a selective cyclooxygenase (COX)-2 inhibitor, could enhance glioblastoma radiosensitivity by inducing tumor necrosis and inhibiting tumor angiogenesis. Methods and Materials: U-87MG cells treated with celecoxib, irradiation, or both were assayed for clonogenic survival and angiogenic factor protein analysis (angiopoietin-1, angiopoietin-2, and vascular endothelial growth factor [VEGF]). In vivo, survival of mice intracranially implanted with U-87MG cells and treated with celecoxib and/or irradiation was monitored. Isolated tumors were assessed for tumor necrosis and tumor microvascular density by von Williebrand's factor (vWF) immunohistochemical staining. Results: Celecoxib (4 and 30 {mu}M; 24, 48,more » and 72 h) enhanced U-87MG cell radiosensitivity by significantly reducing clonogenic survival of irradiated cells. Angiopoietin-1 and VEGF proteins were decreased, whereas angiopoietin-2 expression increased after 72 h of celecoxib alone and when combined with irradiation. In vivo, median survival of control mice intracranially implanted with U-87MG cells was 18 days. Celecoxib (100 mg/kg/day, 2 weeks) significantly extended median survival of irradiated mice (24 Gy total) from 34 to 41 days, with extensive tumor necrosis [24.5 {+-} 8.6% of tumor region, compared with irradiation alone (2.7 {+-} 1.8%)]. Tumor microvascular density was significantly reduced in combined celecoxib and irradiated tumors (52.5 {+-} 2.9 microvessels per mm{sup 2} tumor region), compared with irradiated tumors alone (65.4 {+-} 4.0 microvessels per mm{sup 2}). Conclusion: Celecoxib significantly enhanced glioblastoma radiosensitivity, reduced clonogenic survival, and prolonged survival of glioblastoma-implanted mice by inhibition of tumor angiogenesis with extensive tumor necr0010os.« less
  • Four human cell lines derived from cervical carcinomas (ME-180, SiHa, HT-3, and MS751) and three human cell lines derived from ovarian carcinomas (SK-OV-3, Caov-3, and NIH:OVCAR-3) were analyzed in vitro to determine the effect of recombinant interferon-gamma and recombinant human tumor necrosis factor-alpha on cell growth and survival. The effects of interferon-gamma, tumor necrosis factor-alpha, and both interferon-gamma and tumor necrosis factor-alpha on cell growth were measured after 24 and 72 hours of incubation by the incorporation of chromium 51. The results of this analysis showed that all seven cell lines were resistant to the antiproliferative action of tumor necrosismore » factor-alpha, that the growth of most cell lines was inhibited by interferon-gamma by 72 hours of incubation, and that after 72 hours of incubation all cell lines demonstrated a synergistic antiproliferative response to the combination of interferon-gamma and tumor necrosis factor-alpha. However, the effects of these cytokines on cell growth were found to differ among cell lines and varied with the concentration and the duration of incubation. The growth of one cell line (Caov-3) was stimulated by both tumor necrosis factor-alpha and interferon-gamma. These results suggest that the clinical effects of these cytokines on the growth of gynecologic cancers may be more complex than previously supposed.« less